JP2009512705A - Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体 - Google Patents

Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体 Download PDF

Info

Publication number
JP2009512705A
JP2009512705A JP2008536749A JP2008536749A JP2009512705A JP 2009512705 A JP2009512705 A JP 2009512705A JP 2008536749 A JP2008536749 A JP 2008536749A JP 2008536749 A JP2008536749 A JP 2008536749A JP 2009512705 A JP2009512705 A JP 2009512705A
Authority
JP
Japan
Prior art keywords
mmol
solution
product
added
etoac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008536749A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009512705A5 (enExample
Inventor
ラグラン ラマンサン，
アニマ ゴーサル，
マイケル ダブリュー． ミラー，
スワパン ケー． チョードリー，
ケビン ビー． オールトン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2009512705A publication Critical patent/JP2009512705A/ja
Publication of JP2009512705A5 publication Critical patent/JP2009512705A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2008536749A 2005-10-21 2006-10-18 Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体 Pending JP2009512705A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/255,643 US7825121B2 (en) 1999-05-04 2005-10-21 Piperazine derivatives useful as CCR5 antagonists
PCT/US2006/040636 WO2007050375A2 (en) 2005-10-21 2006-10-18 Piperazine derivatives useful as ccr5 antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012007201A Division JP2012072195A (ja) 2005-10-21 2012-01-17 Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体

Publications (2)

Publication Number Publication Date
JP2009512705A true JP2009512705A (ja) 2009-03-26
JP2009512705A5 JP2009512705A5 (enExample) 2012-03-22

Family

ID=37872167

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008536749A Pending JP2009512705A (ja) 2005-10-21 2006-10-18 Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体
JP2012007201A Pending JP2012072195A (ja) 2005-10-21 2012-01-17 Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012007201A Pending JP2012072195A (ja) 2005-10-21 2012-01-17 Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体

Country Status (17)

Country Link
US (1) US7825121B2 (enExample)
EP (1) EP1951708B1 (enExample)
JP (2) JP2009512705A (enExample)
KR (1) KR20080058486A (enExample)
CN (1) CN101326178A (enExample)
AR (1) AR058105A1 (enExample)
AU (1) AU2006306491B2 (enExample)
BR (1) BRPI0617731A2 (enExample)
CA (1) CA2626565A1 (enExample)
EC (1) ECSP088378A (enExample)
IL (1) IL190902A0 (enExample)
NO (1) NO20082297L (enExample)
PE (1) PE20070711A1 (enExample)
RU (1) RU2008119652A (enExample)
TW (1) TW200800234A (enExample)
WO (1) WO2007050375A2 (enExample)
ZA (1) ZA200803454B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015518957A (ja) * 2012-05-14 2015-07-06 リチャード ジー． ペステル がんの治療のためのｃｃｒ５の修飾薬の使用
US10952415B2 (en) 2011-03-09 2021-03-23 Richard G. Pestell Prostate cancer cell lines, gene signatures and uses thereof

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0509803A (pt) 2004-04-13 2007-09-18 Incyte Corp derivados de piperazinilpiperidina como antagonistas de receptor de quimiocina
DK1954697T3 (da) * 2005-10-21 2010-06-14 Glaxo Group Ltd Peri-kondenserede tricykliske forbindelser, der er anvendelige som antibakterielle midler
WO2008030853A2 (en) * 2006-09-06 2008-03-13 Incyte Corporation Combination therapy for human immunodeficiency virus infection
WO2010081851A1 (en) 2009-01-14 2010-07-22 Genoscience Pharma Piperidin-4-ylpiperazine compounds for the treatment of hcv infection
GB201118876D0 (en) 2011-11-01 2011-12-14 Astex Therapeutics Ltd Pharmaceutical compounds
US10301281B2 (en) 2014-12-11 2019-05-28 Merck Sharp & Dohme Corp. Crystal forms of a CCR5 antagonist
US12459808B2 (en) 2021-09-13 2025-11-04 Kabushiki Kaisha Toshiba Sensor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002543185A (ja) * 1999-05-04 2002-12-17 シェーリング コーポレイション Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体
JP2004524360A (ja) * 2001-03-29 2004-08-12 シェーリング　コーポレイション Ｃｃｒ５アンタゴニストとして有用なアリールオキシム−ピペラジン

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391865B1 (en) * 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002543185A (ja) * 1999-05-04 2002-12-17 シェーリング コーポレイション Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体
JP2004524360A (ja) * 2001-03-29 2004-08-12 シェーリング　コーポレイション Ｃｃｒ５アンタゴニストとして有用なアリールオキシム−ピペラジン

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6011056927; 久保田和彦他: 薬理学テキスト 第２版１刷, 19870525, ｐ．４４５-４５６，　４６０-４６３, 廣川書店 *
JPN6012022933; Ｊａｙａｒａｍ　Ｒ．　Ｔａｇａｔ　ｅｔ　ａｌ: 'Ｐｉｐｅｒａｚｉｎｅ-Ｂａｓｅｄ　ＣＣＲ５　Ａｎｔａｇｏｎｉｓｔｓ　ａｓ　ＨＩＶ-１　Ｉｎｈｉｂｉｔｏｒｓ．　ＩＶ．　Ｄｉｓｃｏｖｅｒｙ　ｏｆ　１-［（４，６-Ｄｉｍｅｔｈｙｌ-５-ｐｙｒｉｍｉｄｉｎ' Ｊｏｕｒｎａｌ　ｏｆ　Ｍｅｄｉｃｉｎａｌ　Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．４７，　Ｎｏ．１０, 2004, ｐ．２４０５-２４０８ *
JPN6012022934; 医薬品の臨床薬物動態試験について , 20010601 *
JPN6012022935; 非臨床薬物動態試験ガイドラインについて , 19980626 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10952415B2 (en) 2011-03-09 2021-03-23 Richard G. Pestell Prostate cancer cell lines, gene signatures and uses thereof
JP2015518957A (ja) * 2012-05-14 2015-07-06 リチャード ジー． ペステル がんの治療のためのｃｃｒ５の修飾薬の使用
US11633397B2 (en) 2012-05-14 2023-04-25 Richard G. Pestell Use of modulators of CCR5 in the treatment of cancer and cancer metastasis

Also Published As

Publication number Publication date
ZA200803454B (en) 2009-04-29
AU2006306491A1 (en) 2007-05-03
PE20070711A1 (es) 2007-08-11
US20060105964A1 (en) 2006-05-18
KR20080058486A (ko) 2008-06-25
TW200800234A (en) 2008-01-01
IL190902A0 (en) 2008-11-03
US7825121B2 (en) 2010-11-02
EP1951708A2 (en) 2008-08-06
AR058105A1 (es) 2008-01-23
ECSP088378A (es) 2008-05-30
CA2626565A1 (en) 2007-05-03
JP2012072195A (ja) 2012-04-12
NO20082297L (no) 2008-07-21
WO2007050375A2 (en) 2007-05-03
BRPI0617731A2 (pt) 2011-08-02
WO2007050375A3 (en) 2007-06-14
CN101326178A (zh) 2008-12-17
RU2008119652A (ru) 2009-11-27
EP1951708B1 (en) 2013-11-20
AU2006306491B2 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
EP1175401B1 (en) Piperazine derivatives useful as ccr5 antagonists
US6391865B1 (en) Piperazine derivatives useful as CCR5 antagonists
EP1175402B1 (en) Piperidine derivatives useful as ccr5 antagonists
US6689765B2 (en) Piperazine derivatives useful as CCR5 antagonists
EP1421075B1 (en) Piperidine derivatives useful as ccr5 antagonists for the treatment of hiv
JP4248251B2 (ja) Ａｉｄｓの処置に有用なｃｃｒ５アンタゴニスト
JP2012072195A (ja) Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体
JP4589728B2 (ja) Ｃｃｒ５アンタゴニストとして有用なピペリジン誘導体
CA2643323A1 (en) Ccr5 antagonists useful for treating hiv
CN100490811C (zh) 用作ccr5拮抗剂的哌嗪衍生物
HK1088001A (en) Piperazine derivatives useful as ccr5 antagonists
MXPA01011185A (en) Piperazine derivatives useful as ccr5 antagonists
HK1061563B (en) Piperidine derivatives useful as ccr5 antagonists for the treatment of hiv
AU2002329889A1 (en) Piperidine derivatives useful as CCR5 antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111031

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120801

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121120